




PHARMACEUTICAL 2023

Pyxis Oncology Inc.
Rank 184 of 446





PHARMACEUTICAL 2023

Pyxis Oncology Inc.
Rank 184 of 446

The relative strengths and weaknesses of Pyxis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pyxis Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Pyxis Oncology Inc. is the variable Net Income, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 76% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	186,612
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,634
Liabilities, Non-Current	18,921
Other Assets	13,602
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,764
Other Revenues	0
Property and Equipment	11,165
Research and Development	86,129
Selling, General and Administrative Expense	37,352

Output Variable	Value in 1000 USD
Assets	211,379
Liabilities	50,555
Expenses	123,481
Revenues	0
Stockholders Equity	160,824
Net Income	-120,717
Comprehensive Net Income	-120,717
Economic Capital Ratio	119%